Literature DB >> 18162077

Regulation of motivation to self-administer ethanol by mGluR5 in alcohol-preferring (P) rats.

Joyce Besheer1, Sara Faccidomo, Julie J M Grondin, Clyde W Hodge.   

Abstract

BACKGROUND: Emerging evidence indicates that Group I metabotropic glutamate receptors (mGluR1 and mGluR5) differentially regulates ethanol self-administration in several rodent behavioral models. The purpose of this work was to further characterize involvement of Group I mGluRs in the reinforcing effects of ethanol using a progressive ratio schedule of reinforcement.
METHODS: Alcohol-preferring (P) rats were trained to self-administer ethanol (15% v/v) versus water on a concurrent schedule of reinforcement, and the effects of the Group I mGluR antagonists were evaluated on progressive ratio performance. The rats were then trained to self-administer sucrose (0.4% w/v) versus water, and the effects of the antagonists were tested on progressive ratio performance.
RESULTS: The mGluR1 antagonist, 3,4-dihydro-2H-pyrano[2,3]b quinolin-7-yl (cis-4-methoxycyclohexyl) methanone (JNJ 16259685; 0 to 1 mg/kg) and the mGluR5 antagonist, 6-methyl-2-(phenylethynyl) pyridine (MPEP; 0 to 10 mg/kg) dose-dependently reduced ethanol break point. In separate locomotor activity assessments, the lowest effective dose of JNJ 16259685 (0.3 mg/kg) produced a motor impairment, whereas the lowest effective dose of MPEP (3 mg/kg) did not. Thus, the reduction in ethanol break point by mGluR1 antagonism was probably a result of a motor impairment. JNJ 16259685 (0.3 mg/kg) and MPEP (10 mg/kg) reduced sucrose break point and produced motor impairments. Thus, the reductions in sucrose break point produced by both Group I antagonists were probably because of nonspecific effects on motor activity.
CONCLUSIONS: Together, these results suggest that glutamate activity at mGluR5 regulates motivation to self-administer ethanol.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18162077      PMCID: PMC2532085          DOI: 10.1111/j.1530-0277.2007.00570.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  44 in total

1.  Peripheral group I metabotropic glutamate receptors modulate nociception in mice.

Authors:  G Bhave; F Karim; S M Carlton; R W Gereau
Journal:  Nat Neurosci       Date:  2001-04       Impact factor: 24.884

2.  Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats.

Authors:  P J Kenny; N E Paterson; B Boutrel; S Semenova; A A Harrison; F Gasparini; G F Koob; P D Skoubis; A Markou
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

Review 3.  Phenotypic and genotypic characterization of the Indiana University rat lines selectively bred for high and low alcohol preference.

Authors:  James M Murphy; Robert B Stewart; Richard L Bell; Nancy E Badia-Elder; Lucinda G Carr; William J McBride; Lawrence Lumeng; Ting-Kai Li
Journal:  Behav Genet       Date:  2002-09       Impact factor: 2.805

4.  The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice.

Authors:  Neil E Paterson; Svetlana Semenova; Fabrizio Gasparini; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2003-04-08       Impact factor: 4.530

5.  Delayed access to alcohol accelerates self-administration of alcohol on a progressive ratio schedule.

Authors:  Chris Pickering; Tiago Moreira; Sture Liljequist
Journal:  Basic Clin Pharmacol Toxicol       Date:  2007-02       Impact factor: 4.080

6.  mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior.

Authors:  Pia Bäckström; Daniel Bachteler; Sabrina Koch; Petri Hyytiä; Rainer Spanagel
Journal:  Neuropsychopharmacology       Date:  2004-05       Impact factor: 7.853

7.  In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine).

Authors:  Jeffery J Anderson; Margaret J Bradbury; Darlene R Giracello; Deborah F Chapman; Greg Holtz; Jeffrey Roppe; Chris King; Nicholas D P Cosford; Mark A Varney
Journal:  Eur J Pharmacol       Date:  2003-07-18       Impact factor: 4.432

8.  Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking.

Authors:  Michela Tessari; Maria Pilla; Michela Andreoli; Daniel M Hutcheson; Christian A Heidbreder
Journal:  Eur J Pharmacol       Date:  2004-09-19       Impact factor: 4.432

9.  Effects of repeated alcohol deprivations on operant ethanol self-administration by alcohol-preferring (P) rats.

Authors:  Zachary A Rodd; Richard L Bell; Kelly A Kuc; James M Murphy; Lawrence Lumeng; Ting-Kai Li; William J McBride
Journal:  Neuropsychopharmacology       Date:  2003-06-11       Impact factor: 7.853

10.  Attenuation of ethanol self-administration and of conditioned reinstatement of alcohol-seeking behaviour by the antiopioid peptide nociceptin/orphanin FQ in alcohol-preferring rats.

Authors:  Roberto Ciccocioppo; Daina Economidou; Amalia Fedeli; Stefania Angeletti; Friedbert Weiss; Markus Heilig; Maurizio Massi
Journal:  Psychopharmacology (Berl)       Date:  2003-11-18       Impact factor: 4.530

View more
  56 in total

1.  A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers.

Authors:  Carolina L Haass-Koffler; Kimberly Goodyear; Victoria M Long; Harrison H Tran; Antonella Loche; Roberto Cacciaglia; Robert M Swift; Lorenzo Leggio
Journal:  Eur J Pharm Sci       Date:  2017-08-01       Impact factor: 4.384

2.  mGlu receptors and drug addiction.

Authors:  Richard M Cleva; M Foster Olive
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-01-20

Review 3.  Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.

Authors:  M Foster Olive
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

4.  Effects of Group I metabotropic glutamate receptor antagonists on sensitivity to reinforcer magnitude and delayed reinforcement in a delay-discounting task in rats: Contribution of delay presentation order.

Authors:  Justin R Yates; Katherine K Rogers; Benjamin T Gunkel; Nicholas A Prior; Mallory N Hughes; Sara M Sharpe; Hunter L Campbell; Anthony B Johnson; Margaret G Keller; Kerry A Breitenstein; Hansen N Shults
Journal:  Behav Brain Res       Date:  2017-01-12       Impact factor: 3.332

Review 5.  Glutamatergic targets for new alcohol medications.

Authors:  Andrew Holmes; Rainer Spanagel; John H Krystal
Journal:  Psychopharmacology (Berl)       Date:  2013-09-01       Impact factor: 4.530

6.  Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies.

Authors:  Max E Joffe; Samuel W Centanni; Anel A Jaramillo; Danny G Winder; P Jeffrey Conn
Journal:  ACS Chem Neurosci       Date:  2018-06-08       Impact factor: 4.418

Review 7.  Metabotropic glutamate receptor ligands as potential therapeutics for addiction.

Authors:  M Foster Olive
Journal:  Curr Drug Abuse Rev       Date:  2009-01

8.  Nonselective suppression of operant ethanol and sucrose self-administration by the mGluR7 positive allosteric modulator AMN082.

Authors:  Michael C Salling; Sara Faccidomo; Clyde W Hodge
Journal:  Pharmacol Biochem Behav       Date:  2008-06-14       Impact factor: 3.533

Review 9.  Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity.

Authors:  Richard L Bell; Helen J K Sable; Giancarlo Colombo; Petri Hyytia; Zachary A Rodd; Lawrence Lumeng
Journal:  Pharmacol Biochem Behav       Date:  2012-07-25       Impact factor: 3.533

10.  mGluR1 within the nucleus accumbens regulates alcohol intake in mice under limited-access conditions.

Authors:  Emily N Lum; Rianne R Campbell; Charlotte Rostock; Karen K Szumlinski
Journal:  Neuropharmacology       Date:  2014-01-24       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.